Publications by authors named "Laura Bruzek"

Claim this Profile
A
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Cynthia Ma, Sumithra J Mandrekar, Steven R Alberts, Gary A Croghan, Aminah Jatoi, Laura Bruzek

Cancer Chemother Pharmacol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Jeffrey E Lancet, Ivana Gojo, Jason Gotlib, Eric J Feldman, Jacqueline Greer, Laura M Bruzek

Blood· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.
Chunrong Yu, Laura M Bruzek, Xue Wei Meng, Gregory J Gores, Christopher A Carter

Oncogene· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
Laura M Bruzek, Jenny N Poynter, Scott H Kaufmann, Alex A Adjei

Mol Pharmacol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
Patricia M Lorusso, Alex A Adjei, Mary Varterasian, Shirish Gadgeel, Joel Reid, Laura Bruzek

J Clin Oncol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Grace K Dy, James P Thomas, George Wilding, Laura Bruzek, Sumithra Mandrekar

Clin Cancer Res· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Grace K Dy, Laura M Bruzek, Gary A Croghan, Sumithra Mandrekar, Charles Erlichman

Clin Cancer Res· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Melissa Alsina, Rafael Fonseca, Edward F Wilson, A Nelida Belle, Elvira Gerbino, Laura M Bruzek

Blood· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.
Joya Chandra, Jennifer Hackbarth, Son Le, David Loegering, Nancy Bone, Laura M Bruzek

Blood· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
Alex A Adjei, Gary A Croghan, Charles Erlichman, Randolph S Marks, Joel M Reid, Laura M Bruzek

Clin Cancer Res· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
Alex A Adjei, Ann Mauer, Laura Bruzek, Randolph S Marks, Shauna Hillman

J Clin Oncol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis